LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics that restore synapses...
Five posters to be presented including new long-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in FOS...
MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform...
Vancouver, British Columbia--(Newsfile Corp. - November 25, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the...
- Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been...
November 22, 2024 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the...
Prospective FORESEE trial of CNSide Cerebrospinal Fluid (CSF) Assay met key primary and secondary endpoints CNSide CSF Assay influenced clinical...
Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad...
NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global telerehabilitation systems market...
JACKSONVILLE, Fla., Nov. 21, 2024 /PRNewswire/ -- By combining resources and expertise, Brooks Rehabilitation, Nemours Children's Health, Jacksonville, Wolfson Children's...
Symposium gathered top fighters, neuroscientists, and media together in New York City on eve of UFC 309 UFC Performance Institute leader,...
Startup Leverages ISS National Lab to Test Viral Vector That Delivers Gene Therapy KENNEDY SPACE CENTER, Fla., Nov. 21, 2024...
NEW YORK, Nov. 21, 2024 /PRNewswire/ -- Cause of a Kind, an award-winning leader in software and web development, has partnered...
CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on...
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the...
DehydraTECH-liraglutide and a select DehydraTECH-CBD formulation were the top performing groups in the Study outperforming the Rybelsus® control group in...
Reductions also seen in comorbid anxiety and depression symptomsBURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay...
CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company...
Company is evaluating IMSB301 in a Phase 1 clinical trial in healthy volunteers and plans to move rapidly into Phase...
- Candidate VY1706 demonstrates significant reductions of tau at low doses in NHP study; IND and CTA filings anticipated in...